MedTrace Logo

Community-based Sero-epidemiological Study of COVID-19

NCT05599555 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 9600

Last updated 2024-12-11

No results posted yet for this study

Summary

Using detailed serial cross-sectional estimates of the age-specific distribution of SARS-CoV-2 Omicron variant-specific antibody positivity levels, the investigators derived age-specific infection attack rates and age-specific population immunity levels and tracked the magnitude of individual-level and population-level waning immunity over time. The findings will inform health policy makers on devising future public health and social measures and vaccination guidance in response to the ongoing COVID-19 pandemic.

Conditions

Interventions

BIOLOGICAL

mRNA BNT162b2 vaccine

mRNA vaccine Comirnaty (BNT162b2 mRNA, BioNTech/Fosun-Pharma, Mainz, Germany/Shanghai, China)

BIOLOGICAL

CoronaVac vaccine

Inactivated CoronaVac vaccine (Sinovac Life Sciences, Beijing, China)

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Joseph T Wu · The University of Hong Kong

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-28
Primary Completion
2022-12-31
Completion
2023-03-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05599555 on ClinicalTrials.gov